Prevalence and outcomes of Covid-19 in Parkinson's disease: Acute settings and hospital.

Int Rev Neurobiol

Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital-UHN, Division of Neurology, University of Toronto, Toronto, ON, Canada; Krembil Research Institute, Toronto, ON, Canada; Center for Advancing Neurotechnological Innovation to Application (CRANIA), Toronto, ON, Canada. Electronic address:

Published: October 2022

The global explosion of COVID-19 necessitated the rapid dissemination of information regarding SARS-CoV-2. Hence, COVID-19 prevalence and outcome data in Parkinson's disease patients were disseminated at a time when we only had part of the picture. In this chapter we firstly discuss the current literature on the prevalence of COVID-19 in people with PD. We then discuss outcomes from COVID-19 in people with PD, specifically risk of hospitalization and mortality. Finally, we discuss specific contributing and confounding factors which may put PD patients at higher or lower risk from COVID-19.

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020798	PMC
http://dx.doi.org/10.1016/bs.irn.2022.03.001	DOI Listing

Publication Analysis

Top Keywords

outcomes covid-19

parkinson's disease

covid-19 people

covid-19

prevalence outcomes

covid-19 parkinson's

disease acute

acute settings

settings hospital

hospital global

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!